Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

Mol Imaging Biol. 2019 Feb;21(1):191. doi: 10.1007/s11307-018-1287-7.

Lanell M Peterson¹, Brenda F Kurland^{2

3}, Erin K Schubert^{4

5}, Jeanne M Link⁶, V K Gadi^{2

7}, Jennifer M Specht^{2

7}, Janet F Eary⁶, Peggy Porter², Lalitha K Shankar⁸, David A Mankoff^{4

5}, Hannah M Linden^{2

7}

¹ Radiology/Nuclear Medicine, University of Washington Medical Center-Seattle Cancer Care Alliance, Seattle, WA, USA. lanell@uw.edu.
² Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
³ Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.
⁴ Radiology/Nuclear Medicine, University of Washington Medical Center-Seattle Cancer Care Alliance, Seattle, WA, USA.
⁵ Radiology/Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁶ Radiology/Nuclear Medicine, University of Washington Medical Center, Seattle, WA, USA.
⁷ Medical Oncology, University of Washington Medical Center-Seattle Cancer Care Alliance, Seattle, WA, USA.
⁸ Cancer Imaging Program, National Cancer Institute, Bethesda, MD, USA.

Abstract

Two data points from Table 1. (continued) were published in error. The corrected data in Table 1. (continued) are shown, in italic, below.